Rabin Medical Center, Gynecologic Oncology Division, The Helen Schnieder Hospital for Women, Tel Aviv University, Sackler School of Medicine, Petah Tikva, Israel.
Am J Clin Oncol. 2013 Oct;36(5):472-4. doi: 10.1097/COC.0b013e3182549399.
Women suffering from recurrent platinum-resistant ovarian carcinoma go through several lines of chemotherapy, but eventually fail all conventional chemotherapy options. After failing multiple other regimens, we offer patients fluorouracil (5-FU) in a weekly regimen with leucovorin. For those women who failed to react to multiple lines of treatment, 5-FU has been shown to be a reasonable option with reported response rates of 10% to 33%. We report our experience with 5-FU+leucovorin in this patient population.
This is a retrospective chart review of women treated for recurrent ovarian carcinoma between January 2003 and December 2009. Women with recurrent ovarian carcinoma who had been treated with at least 3 previous chemotherapy regimens and had received 5-FU were eligible for the study. 5-FU and leuocovorin are given at 600 mg/m weekly for 6 weeks of an 8-week cycle. Patient charts were reviewed for demographics and disease history relevant to the administration of 5-FU. Response was assessed clinically and by CA125 levels.
Fifty-three patients matching inclusion criteria received 5-FU during the study period. Twenty-five percent of patients achieved a partial response and 17% stable disease for an overall response rate of 42%. A median of 4 weekly doses was administered (range, 1 to 26). The median survival of the whole cohort was 10 weeks after the last dose of 5-FU was administered.
In this population of heavily pretreated patients, a significant response to 5-FU can be achieved. Unfortunately, the response is short lived and mostly partial.
患有复发性铂耐药卵巢癌的女性会经历数线化疗，但最终会对所有常规化疗方案均无反应。在多次其他方案失败后，我们为患者提供每周氟尿嘧啶（5-FU）联合亚叶酸治疗。对于那些对多线治疗无反应的女性，5-FU 已被证明是一种合理的选择，其报告的缓解率为 10%至 33%。我们报告了在这一患者群体中使用 5-FU+亚叶酸的经验。
这是一项对 2003 年 1 月至 2009 年 12 月期间接受复发性卵巢癌治疗的女性进行的回顾性图表审查。患有复发性卵巢癌、接受过至少 3 种先前化疗方案且接受过 5-FU 治疗的女性有资格参加该研究。5-FU 和亚叶酸以 600mg/m 的剂量每周给予 6 周，8 周为一个周期。对患者的病历进行了与 5-FU 给药相关的人口统计学和疾病史的审查。通过 CA125 水平评估临床和客观缓解。
在研究期间，符合纳入标准的 53 名患者接受了 5-FU 治疗。25%的患者达到部分缓解，17%的患者疾病稳定，总缓解率为 42%。中位 4 个周剂量（范围为 1 至 26）给予。整个队列的中位生存期为末次 5-FU 剂量后 10 周。
在这群接受过多线治疗的患者中，5-FU 可以取得显著的缓解。不幸的是，缓解持续时间短，且大多为部分缓解。
